Psychedelic drug stocks represent (by far) the best new opportunity in life sciences today. Institutional capital is flooding into the sector. But market analysts are asleep-at-the-wheel here.
Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study
Cybin announces two new drug candidates for its R&D pipeline as its pre-clinical research deepens.
Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing
Field Trip closes on a CAD$95 million bought deal financing, nearly double the original CAD$50 million offering.
Psychedelic Drug Development Or Clinics: Which Is The Better Path To Investor Profits?
Drug development or mental health clinics? We explore the benefits of both business strategies for investors in psychedelic stocks.
Red Light Holland Successfully Completes Sale and Import of iMicrodose Psychedelic Truffles into Canada Under a Health Canada Approved Psilocybin Import Permit
Red Light Holland imports psilocybin truffles into Canada from its Netherlands supply source.
Will Court Challenges Lead To Psychedelics Legalization?
A Seattle doctor is suing the DEA for blocking access to psilocybin. Could this be the quickest road to psychedelic drug legalization?
Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering
Numinus announces a CAD$30 million bought deal financing with units priced at CAD$1.25.
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
MINDCURE's new COO, Tarik Lebbadi, recently led an international division of Johnson & Johnson.
Psychedelic Drugs And The Placebo Effect
Part of the benefit from psychedelic medicine may actually be a Placebo Effect. Find out why that is actually a GOOD thing.
Numinus to expand state-of-the-art psychedelics research laboratory
Numinus expands its research lab, including more research space, supply capacity and accelerated IP development.
COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020
Compass expecting to report data from its Phase IIb study by the end of 2021. Cash on hand decreases to $190.3 million, from $196.5 million the previous quarter.
Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition
Adelia Therapeutics, a subsidiary of Cybin Corp., achieves API synthesis and optimization on trypatmine derivatives.
